Excelsior Biopharma Cash Flow Reinvestment Rate
Excelsior Biopharma cash flow reinvestment rate. Excelsior Biopharma (6496) has a Cash Flow Reinvestment Rate of 6.86x as of June 2025, reinvesting NT$26.07 Million (capex NT$14.44 Million plus investments NT$-11.63 Million) from operating cash flow of NT$3.80 Million. Explore Excelsior Biopharma (6496) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Excelsior Biopharma (2017–2022)
Cash flow reinvestment rate of Excelsior Biopharma from 2017 to 2022. Historical reinvestment intensity for Excelsior Biopharma across 5 annual periods. Explore 6496 capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Excelsior Biopharma Cash Flow Reinvestment Rate by Year (2017–2022)
Excelsior Biopharma cash flow reinvestment rate by year from 2017 to 2022. Year-by-year capital reinvestment analysis for Excelsior Biopharma. For the full cash flow conversion analysis, see Excelsior Biopharma cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 37.88x | NT$207.78 Million | NT$5.49 Million | NT$7.78 Million | ▲ +23704.4% |
| 2021 | 0.16x | NT$8.88 Million | NT$55.82 Million | NT$2.88 Million | ▲ +89.2% |
| 2020 | 0.08x | NT$43.80 Million | NT$520.81 Million | NT$11.62 Million | ▼ -74.3% |
| 2018 | 0.33x | NT$41.51 Million | NT$126.92 Million | NT$9.54 Million | ▲ +524.0% |
| 2017 | 0.05x | NT$18.32 Million | NT$349.47 Million | NT$18.10 Million | — |